---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-000928"
form_type: "8-K"
ticker: null
cik: "0001662244"
company_name: "Cyteir Therapeutics, Inc."
filed_at: "2023-01-19T23:59:59+00:00"
generated_at: "2026-06-20T13:09:27.331836+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Cyteir cuts 70% of staff, focuses CYT-0851 on ovarian cancer, extends cash runway to 2026

## Summary
- Workforce reduction of ~70%; expects 15 or fewer employees; charges $2.5M-$3M in Q1 2023.
- Strategic focus on CYT-0851 + capecitabine for platinum-resistant ovarian cancer; Phase 2 monotherapy suspended.
- Preliminary combo: 13 patients, 5 ovarian cancer patients showed responses/disease stabilization at 300-400mg doses.
- Cash runway extended into 2026; $147M cash as of Dec 31, 2022 (unaudited).
- CBO Gengos (Feb 3) and CSO Secrist (Apr 1) depart; CEO retention bonus 150% target if stays through Dec 31, 2023.

## SEC filing metadata
- accession: 0000950170-23-000928
- form_type: 8-K
- cik: 0001662244
- company_name: Cyteir Therapeutics, Inc.
- filed_at: 2023-01-19T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.05, 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1662244/000095017023000928/0000950170-23-000928-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1662244/000095017023000928/cyt-20230112.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-000928
- JSON: https://secwatch.observer/filing/0000950170-23-000928.json
- Plain text: https://secwatch.observer/filing/0000950170-23-000928.txt

## Key facts
- Executive change
  Paul Secrist departed as Chief Scientific Officer at Cyteir Therapeutics, Inc..
  - Action: will separate
  - Role: Chief Scientific Officer
  source text: Andrew Gengos, the Company’s Chief Business Officer will separate from the Company effective February 3, 2023 and Paul Secrist, Ph.D., the Company’s Chief Scientific Officer will separate from the Company effective April 1, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1662244/000095017023000928/0000950170-23-000928-index.htm
- Executive change
  Andrew Gengos departed as Chief Business Officer at Cyteir Therapeutics, Inc..
  - Action: will separate
  - Role: Chief Business Officer
  source text: Andrew Gengos, the Company’s Chief Business Officer will separate from the Company effective February 3, 2023 and Paul Secrist, Ph.D., the Company’s Chief Scientific Officer will separate from the Company effective April 1, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1662244/000095017023000928/0000950170-23-000928-index.htm
- Restructurings & Charges
  Cyteir Therapeutics, Inc. announced a restructuring with charges of approximately $2.5 million to $3 million affecting Company (approximately 70% of the Company’s workforce).
  - Type: restructuring
  - Charge: approximately $2.5 million to $3 million
  - Affected area: Company
  - Headcount: approximately 70% of the Company’s workforce
  source text: the Company expects to have 15 or fewer full-time employees. The Company estimates that, in connection with these changes, it will incur aggregate charges of approximately $2.5 million to $3 million, all of which are anticipated to result in future cash expenditures, primarily for one-time employee severance and benefit costs, the majority of which are expected
  evidence_url: https://www.sec.gov/Archives/edgar/data/1662244/000095017023000928/0000950170-23-000928-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.